a head-to-head trial has found that lilly's glp-1 pill outperformed novo's rybelsus. the outcome of this trial may impact the market for obesity and diabetes treatments, which is also influenced by other factors such as compounders and approvals. the results have sparked various developments, including a lawsuit from novo and fda approvals that may reshape the competitive landscape.